Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 7-Ethyl-10-Hydroxycamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 17/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL34018 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29359781 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29787648 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL16072280 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL733477 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29354078 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL27680702 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL28292269 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL1454961 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL30739326 | 0.95 | MEN1 (0.91) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168352-A1 | HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF | YALE UNIVERSITY (US) | 2023-09-07 | — | — | WO | claimed |
| EP-3981434-A1 | ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND MEDICINAL USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |
| WO-2020244657-A1 | ANTI-B7-H4 ANTIBODY–DRUG CONJUGATE AND MEDICINAL USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-10 | — | — | WO | disclosed |
| US-9687558-B2 | Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-06-27 | — | — | US | disclosed |
| US-9687558-B2 | Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation, and their use in the pharmaceutical field | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-06-27 | — | — | US | disclosed |
| EP-3145922-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | Molecular Targeting Technologies, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015179299-A1 | DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | MOLECULAR TARGETING TECHNOLOGIES, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
| WO-2011002852-A2 | PRO-DRUG COMPLEXES AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010150255-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2010-12-29 | — | — | WO | disclosed |
| US-7683170-B2 | Methods for preparing Irinotecan | W. C. HERAEUS GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7683170-B2 | Methods for preparing Irinotecan | W. C. HERAEUS GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20080292703-A1 | Antitumoral Bioconjugates of Hyaluronic Acid or Its Derivatives Obtained by Indirect Chemical Conjugation, and Their Use in the Pharmaceutical Field | FIDIA FARMACEUTICI S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-7378555-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378555-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | W. C. HERAEUS GMBH (DE) | 2007-06-14 | — | — | US | disclosed |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | W. C. HERAEUS GMBH (DE) | 2007-06-14 | — | — | US | disclosed |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | PAICS, DHPS, TOP2A | TOP1 6/4885MEN1 2581/4885KMT2A 2593/4885 |
| US-20080292703-A1 | Antitumoral Bioconjugates of Hyaluronic Acid or Its Derivatives Obtained by Indirect Chemical Conjugation, and Their Use in the Pharmaceutical Field | CD44, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPSE | TOP1 784/4885MEN1 658/4885KMT2A 2438/4885 |
| US-20070135471-A1 | METHODS FOR PREPARING IRINOTECAN | TYMP, PNP, PAICS | TOP1 6/4885MEN1 1849/4885KMT2A 2380/4885 |
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | TOP1 98/4885MEN1 2124/4885KMT2A 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.